At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 12, 2026 at 16:01 ET
Corvus Pharmaceuticals reported financial results for Q4 and full year 2025, highlighted by positive Phase 1 atopic dermatitis trial data for soquelitinib, initiation of a Phase 2 trial in the same indication, and a successful $189 million public offering extending cash runway into Q2 2028. Despite increased R&D spending and a slight YoY increase in net loss, the company is advancing multiple clinical programs with upcoming data catalysts.
- Positive Phase 1 data in atopic dermatitis: 75% of soquelitinib patients achieved EASI 75 vs. 20% placebo; no severe adverse events.
- Initiated Phase 2 atopic dermatitis trial with ~200 patients; additional Phase 2 trials in asthma and hidradenitis suppurativa planned for 2026.
- Completed public offering raising $189.4 million in net proceeds, extending cash runway into Q2 2028.
- Cash, cash equivalents, and marketable securities: $56.8 million as of December 31, 2025 (excluding $189.4 million from January 2026 financing).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access